New Blood Test May Predict Alzheimer’s Disease Risk

Dr. Jeremy Koppel introduces a new blood test that marks progress in predicting Alzheimer’s disease. This test identifies abnormal protein accumulation, aiding diagnosis for symptomatic individuals.

A recent Finnish study suggests early-onset Alzheimer’s might be signaled by certain medical conditions years before diagnosis. Depression, vertigo, and headaches were more common in the five years before diagnosis, offering early detection hints.

Researchers reviewed medical records of 407 early-onset Alzheimer’s patients and 4,035 similar individuals without the diagnosis, looking back 15 years before diagnosis.

The average diagnosis age was 60, with early-onset Alzheimer’s seen in those under 65.

Data from the study highlighted significant condition prevalence among diagnosed individuals:

• Vertigo: 5.9% vs. 2.1%
• Depression: 5.7% vs. 2.3%
• Headache: 4.9% vs. 1.6%
• Stroke: 4.4% vs. 2.0%
• Alcohol-related disorders: 3.4% vs. 1.4%
• Brain disorders: 2.9% vs. 0.9%
• Thyroid disorders: 2.5% vs. 0.8%
• Epilepsy: 2.2% vs. 0.7%
• Delirium: 1.5% vs. 0.1%
• Ear, nose, and throat disorders: 5.2% vs. 2.9%

Dr. Suvi-Johanna Krüger explained the significant increase in healthcare visits for Alzheimer’s patients close to diagnosis, indicating emerging symptoms. This corroborates knowledge of neuropathological changes in Alzheimer’s starting 15-20 years prior to symptoms.

This observational study showed associations but couldn’t confirm these conditions as predictors for Alzheimer’s. The findings don’t establish causality; they suggest these conditions might be risk factors or early symptoms.

Limitations include the inability to independently verify all diagnoses and applicability limited to Finland’s population. Larger studies on biomarkers and genetics might clarify causal relationships.

Dr. Krüger emphasized early diagnosis as it offers more treatment opportunities. It also provides individuals and families time to plan and access support services.

Persistent symptoms require health provider attention. Early diagnosis provides more treatment and support options in Alzheimer’s initial stages.